Logo

NEWSBRIEF: Caliper CEO Kisner Steps Down, Replaced by Company Co-founder

May 13, 2002

SAN FRANCISCO, May 13 - Caliper Technologies named Michael Knapp to replace Daniel Kisner as CEO, the company said today.

 

Knapp, a Caliper founder and vice president of corporate development, will step into the CEO position as of July 1, when Kisner will become chairman of the board, according the company.

 

Kisner also will relinquish his responsibilities as president, which will be filled by James Knighton, who will also serve in his current role as chief financial officer of the company.

 

A company spokesperson said the moves did not signal a change in Caliper's business plan and was intended to allow Kisner to "balance professional and family needs."

 

Kisner will be on site at the company's Mountain View, Calif.headquarters one or two days per week as chairman, according to the spokesperson.

 

David Milligan, Caliper's current chairman, will become vice chairman.

 

Click here for more information.

 

Breaking News
The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.